Authors
1 Department of Internal Medicine and Division of Hematology, Isfahan University of Medical Sciences, Isfahan, Iran
2 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Acute myeloid leukemia (AML) is the most common type of leukemia. In this study, outcome of intensive chemotherapy in patients treated in a large urban public university hospital in a developing country was investigated.
Materials and Methods: The records of all patients treated for AML with 3 + 7 protocol from 2002 to 2010 were analyzed.
Results: Among 95 patients, 34 (35.8%) were female and 61 (64.2%) were male patients. Patients' median age was 37 years, ranging 15-68 years. Complete remission (CR) was observed in 56 (58.9%) of patients treated with this protocol. Median overall survival was 13 months (95% CI: 8.8-17.1 months). The 1-year AML survival rate was 51%, and 2-year survival rate was 26%.
Conclusion: Our study shows that in our center in Iran, CR rates and median overall survival rates after induction chemotherapy are less than developed countries.
Keywords
1. | Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-51. [PUBMED] |
2. | Howlader NN, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. Available from: http://www.seercancergov/csr/1975_2008/(based on November 2010 SEER data submission, posted to the SEER web site). |
3. | Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-9. [PUBMED] |
4. | Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59. [PUBMED] |
5. | Flasshove M, Meusers P, Schütte J, Noppeney R, Beelen DW, Sohrab S, et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann Hematol 2000;79:533-42. |
6. | Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004;18:989-97. [PUBMED] |
7. | Deschler B, Lübbert M. Acute myeloid leukemia: Epidemiology and etiology. Cancer 2006;107:2099-107. |
8. | Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010;115:453-74. |
9. | Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8. [PUBMED] |
10. | Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9. |
11. | Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol 1997;24:57-69. [PUBMED] |
12. | Eivazi-Ziaei J. Control of acute myeloid leukemia morbidity in northwest Iran. Asian Pac J Cancer Prev 2005;6:472-3. [PUBMED] |
13. | Löwenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003:82-101. |
14. | Pulcheri W, Spector N, Nucci M, de Morais JC, Pimenta G, de Oliveira HP. The treatment of acute myeloid leukemia in Brazil: Progress and obstacles. Haematologica 1995;80:130-5. [PUBMED] |
15. | Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: A report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010;116:5012-21. [PUBMED] |
16. | Acute myeloid leukemia. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 2012. Available from: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. [Last cited on 6 Feb 2012]. |
17. | Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010;116:3147-56. [PUBMED] |